These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36481253)

  • 1. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder.
    Rahman SN; Lokeshwar SD; Syed JS; Javier-Desloges JF; Press BH; Choksi AU; Rajwa P; Pradere B; Ploussard G; Kim JW; Monaghan TF; Renzulli JR; Shariat SF; Leapman MS
    Urol Oncol; 2023 Feb; 41(2):107.e1-107.e8. PubMed ID: 36481253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.
    Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD
    JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Variant Histology on Occult Nodal Metastasis after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Review of the National Cancer Database.
    Fu M; Klose C; Sparks A; Whalen M
    Clin Genitourin Cancer; 2022 Apr; 20(2):e135-e139. PubMed ID: 34961704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
    Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
    Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
    Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M
    Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
    Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
    Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
    J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program.
    Diamantopoulos LN; Holt SK; Khaki AR; Sekar RR; Gadzinski A; Nyame YA; Vakar-Lopez F; Tretiakova MS; Psutka SP; Gore JL; Lin DW; Schade GR; Hsieh AC; Lee JK; Yezefski T; Schweizer MT; Cheng HH; Yu EY; True LD; Montgomery RB; Grivas P; Wright JL
    Clin Genitourin Cancer; 2021 Apr; 19(2):144-154. PubMed ID: 33160889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.
    Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G
    Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy.
    Faiena I; Salmasi A; Mendhiratta N; Lenis AT; Pooli A; Drakaki A; Gollapudi K; Blumberg J; Pantuck AJ; Chamie K
    World J Urol; 2018 Nov; 36(11):1825-1833. PubMed ID: 29752514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy.
    Fairey AS; Daneshmand S; Wang L; Schuckman A; Lieskovsky G; Djaladat H; Cai J; Miranda G; Skinner EC
    Urol Oncol; 2014 Feb; 32(2):110-6. PubMed ID: 23499168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy.
    Sekar RR; Diamantopoulos LN; Bakaloudi DR; Khaki AR; Grivas P; Winters BR; Vakar-Lopez F; Tretiakova MS; Psutka SP; Holt SK; Gore JL; Lin DW; Schade GR; Hsieh AC; Lee JK; Yezefski T; Schweizer MT; Cheng HH; Yu EY; True LD; Montgomery RB; Wright JL
    Clin Genitourin Cancer; 2023 Aug; 21(4):507.e1-507.e14. PubMed ID: 37150667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder.
    Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A
    Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Neoadjuvant Chemotherapy on Pathologic Downstaging in Patients With Variant Histology Undergoing Radical Cystectomy.
    Campbell RA; Khanna A; Boorjian SA; Knorr J; Cox R; Nicholas M; Cheville J; Sharma V; Murthy PB; Tarrell R; Thapa P; Tollefson MK; Thompson RH; Frank I; Karnes RJ; Haber GP; Lee B
    Clin Genitourin Cancer; 2024 Apr; 22(2):157-163.e1. PubMed ID: 38008690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
    Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
    Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
    Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
    Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longer time to radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes.
    Nuijens ST; van Osch FHM; van Hoogstraten LMC; Witjes JA; Aben KKH; Hermans TJN
    Urol Oncol; 2024 Apr; 42(4):117.e11-117.e16. PubMed ID: 38238116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
    Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
    J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
    Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
    Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.